Jump to content


The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

  • Press release - 14/03/2024

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

  • Press release - 06/02/2024

    BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).

  • Press release - 05/01/2024

    More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

  • Press release - 18/12/2023

    For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

  • Press release - 15/11/2023

    Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.

  • Press release - 25/10/2023

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

  • Dossier - 11/10/2023

    From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.

  • Press release - 21/09/2023

    Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

  • Press release - 13/07/2023

    Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…

  • Expert interview - 05/07/2023

    The life sciences sector consumes huge quantities of energy and resources. This needs to change and we have to think differently. But how and where can sustainability measures be sensibly applied in the laboratory without compromising the quality of research results? Dr. Kerstin Hermuth-Kleinschmidt, owner of NIUB-Nachhaltigkeitsberatung, a company from Freiburg that focuses on sustainability in life sciences, tells BIOPRO how this can be done.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/pharma